Abstract | OBJECTIVE: PATIENTS AND METHODS: Materials and methods: Fifteen patients with primary bone Ewing sarcoma received treatment with trofosfamide (150 mg/m2 p.o. days 1-10) every 28 days. All patients had standard tumour imaging and laboratory evaluation. All toxicities were documented. RESULTS: Results: A total of 90 cycles (median 5 cycles/patient) were administered. A complete response was maintained in nine patients, while six patients had disease progression during treatment. Median time to progression was 1.9 months (range 1.8 to 4.6). Eleven patients (73.3%) are alive including nine with no evidence of disease with a median follow-up of 3.9 years (range 1.4 to 7.6). All patients with active disease at the start of the trofosfamide treatment died. There were no significant toxicities. CONCLUSION: Conclusions: Treatment with trofosfamide is well-tolerated and could have a role to maintain response in patients with primary bone Ewing sarcoma. Further studies are needed to better define the use of this regimen in the upfront management of those patients.
|
Authors | Anna Raciborska, Katarzyna Bilska, Carlos Rodriguez-Galindo |
Journal | Developmental period medicine
(Dev Period Med)
Vol. 23
Issue 1
Pg. 39-44
( 2019)
ISSN: 2354-0060 [Electronic] Poland |
PMID | 30954980
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Cyclophosphamide
- trofosfamide
|
Topics |
- Adolescent
- Antineoplastic Agents, Alkylating
(adverse effects, therapeutic use)
- Bone Neoplasms
(diagnosis, diagnostic imaging, drug therapy)
- Child
- Child, Preschool
- Cyclophosphamide
(adverse effects, analogs & derivatives, therapeutic use)
- Female
- Humans
- Male
- Sarcoma, Ewing
(diagnosis, diagnostic imaging, drug therapy)
- Treatment Outcome
- Young Adult
|